'The treatment paradigm for relapsed/refractory chronic lymphocytic leukemia (CLL) is slowly expanding, with clinical trials starting and a new generation of drugs being ushered in, says Susan M. O'Brien, MD.
In an interview with OncLive, O’Brien, MD, hematologist, oncologist, UC Irvine Health Chao Family Comprehensive Cancer Center, discusses upcoming novel treatments in relapsed/refractory CLL, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.'
OncLive interview with Dr O'Brien:
duvelisib in trial versus ofatumumab (Arzerra)
TGR-1202 (PI3K inhibitor)
acalabrutinib, (ACP-196) a next-generation BTK inhibitor
Thoughts on RESONATE-2 data chlorambucil with ibrutinib in patients 65 years or older)
Photo: White eared honeyeater